Las Vegas, NV -- (SBWIRE) -- 10/31/2013 -- EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more .EquityObserver.com issues a special report on the following stocks: Meritor Inc (NYSE:MTOR), Hanwha Solarone Co Ltd (NASDAQ:HSOL), Tangoe Inc (NASDAQ:TNGO), Celldex Therapeutics, Inc. (NASDAQ:CLDX)
Meritor Inc (NYSE:MTOR) managed to keep its fall at -2.78% on above-normal volume of 2.32M shares. The stock settled at $7 after floating in a range of $6.95 to $7.24. Its latest price has reached market capitalization of $7.20 million. Its 52-week range has been $3.83 to $8.50. Meritor, Inc. (Meritor) is a global supplier of a range of integrated systems and components to original equipment manufacturers (OEMs) and the aftermarket for the commercial vehicle, transportation and industrial sectors.
Has MTOR Found The Bottom and Ready To Move Up? Find Out Here
Hanwha Solarone Co Ltd (NASDAQ:HSOL) traded down on a volume of 2.31 million, lower than its standard daily volume. Shares have dropped -3.53% to $4.23 Over the last twelve months, the stock has gained 306.73% and faced a worst price of $0.77. Hanwha SolarOne Co., Ltd. (Hanwha SolarOne) is an integrated manufacturer of silicon ingots, silicon wafers, PV cells and PV modules in China.
Has HSOL Found The Bottom And Ready To Gain Momentum? Find Out Here
Tangoe Inc (NASDAQ:TNGO) settled -6.24% lower at $19.55 on above-normal volume of 2.31M shares during the last trading day. The stock has its 12-month high at $26.05 and 52-week low price was $11.53. It traded in a range of $19.42 to $20.65 during the last trading day. Tangoe, Inc. (Tangoe) is a global provider of communications lifecycle management (CLM), software and services to a range of enterprises, including large and medium-sized businesses and other organizations.
Will TNGO Get Buyers Even After The Recent Rally? Find Out Here
In the last trading session, Celldex Therapeutics, Inc. (NASDAQ:CLDX) was down on low volume, trading at a volume of 2.30M versus its average daily volume of 3.85 million shares. At $22.79, the stock has attained market capitalization of 1.85 billion. Celldex Therapeutics, Inc. (Celldex), is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases.
Why Should Investors Buy CLDX After the Recent Fall? Just Go Here and Find Out
About Equity Observer:
Equity Observer delivers intra-day insights into the equities, tech and investment world. The website is a window into what’s going on in the business world and why.
EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.
The disclaimer is to be read and fully understood before using our site, or joining our email list.
http://www.equityobserver.com/ has a no tolerance spam policy; we will not sell or re-distribute your email to any 3rd party. A If applicable, please also unsubscribe from the newsletter using the link at the bottom of the email if you no longer wish to receive our emails. We only send our newsletters to opt-in members.
PLEASE NOTE WELL: The http://www.equityobserver.com/" rel="nofollow" href="http://www.equityobserver.com/"> http://www.equityobserver.com/>
Employees and contributors are NOT registered as an Investment Adviser in any jurisdiction whatsoever.
Read Full Disclaimerat: http://www.equityobserver.com/
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)